Cardioprotective effects of intracoronary administration of 4-chlorodiazepam in small and large animal models of ischemia-reperfusion

International Journal of Cardiology

Volumn 224, Issue , 2016, Pages 90-95

  Tsamatsoulis, Michalis ^a   Kapelios, Chris J ^a   Katsaros, Lambros ^a   Vakrou, Stella ^a   Sousonis, Vasilis ^a   Sventzouri, Stefania ^a   Michelinakis, Nicholas ^a   Perrea, Despoina N ^a   Anastasiou Nana, Maria ^a   Malliaras, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute myocardial infarction; No reflow phenomenon; Reperfusion injury

Indexed keywords

4' CHLORODIAZEPAM; 4'-CHLORODIAZEPAM; ANTILIPEMIC AGENT; BENZODIAZEPINE DERIVATIVE; CARDIOTONIC AGENT;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART PROTECTION; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HISTOLOGY; INTRACORONARY DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PIG; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RAT; ST SEGMENT ELEVATION; WISTAR RAT; ANIMAL; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; INTRAARTERIAL DRUG ADMINISTRATION; MYOCARDIAL REPERFUSION INJURY; PROCEDURES; RANDOMIZATION; TREATMENT OUTCOME;

ANIMALS; BENZODIAZEPINONES; CARDIOTONIC AGENTS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; HYPOLIPIDEMIC AGENTS; INFUSIONS, INTRA-ARTERIAL; MALE; MYOCARDIAL REPERFUSION INJURY; RANDOM ALLOCATION; RATS; RATS, WISTAR; SWINE; TREATMENT OUTCOME;

EID: 84987923117     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.09.011     Document Type: Article

References (39)

1. [1] Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994), 311–322.
2. [2] Boersma, E., Primary Coronary Angioplasty vs. Thrombolysis Group, Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur. Heart J. 27 (2006), 779–788.
3. [3] Yellon, D.M., Hausenloy, D.J., Myocardial reperfusion injury. N. Engl. J. Med. 357 (2007), 1121–1135.
4. [4] Hausenloy, D.J., Yellon, D.M., Targeting myocardial reperfusion injury-the search continues. N. Engl. J. Med. 373 (2015), 1073–1075.
5. [5] Hervas, A., de Dios, E., Forteza, M.J., et al. Rev. Esp. Cardiol. (Engl. Ed.) 68 (2015), 928–934.
6. [6] Niccoli, G., Cosentino, N., Spaziani, C., Fracassi, F., Tarantini, G., Crea, F., No-reflow: incidence and detection in the cath-lab. Curr. Pharm. Des. 19 (2013), 4564–4575.
7. [7] Ito, H., Tomooka, T., Sakai, N., et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 85 (1992), 1699–1705.
8. [8] Sorajja, P., Gersh, B.J., Costantini, C., et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur. Heart J. 26 (2005), 667–674.
9. [9] Brosh, D., Assali, A.R., Mager, A., et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am. J. Cardiol. 99 (2007), 442–445.
10. [10] Ito, H., No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat. Clin. Pract. Cardiovasc. Med. 3 (2006), 499–506.
11. [11] Morin, D., Musman, J., Pons, S., Berdeaux, A., Ghaleh, B., Mitochondrial translocator protein (TSPO): from physiology to cardioprotection. Biochem. Pharmacol. 105 (2016), 1–13.
12. [12] James, M.L., Selleri, S., Kassiou, M., Development of ligands for the peripheral benzodiazepine receptor. Curr. Med. Chem. 13 (2006), 1991–2001.
13. [13] Sileikyte, J., Petronilli, V., Zulian, A., et al. Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor). J. Biol. Chem. 286 (2011), 1046–1053.
14. [14] Patel, J., Marangos, P.J., Differential effects of GABA on peripheral and central type benzodiazepine binding sites in brain. Neurosci. Lett. 30 (1982), 157–160.
15. [15] Le Fur, G., Vaucher, N., Perrier, M.L., et al. Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci. 33 (1983), 449–457.
16. [16] Li, J., Xiao, J., Liu, Y., et al. Mitochondrial benzodiazepine receptors mediate cardioprotection of estrogen against ischemic ventricular fibrillation. Pharmacol. Res. 60 (2009), 61–67.
17. [17] Akar, F.G., Aon, M.A., Tomaselli, G.F., O'Rourke, B., The mitochondrial origin of postischemic arrhythmias. J. Clin. Invest. 115 (2005), 3527–3535.
18. [18] Brown, D.A., Aon, M.A., Akar, F.G., Liu, T., Sorarrain, N., O'Rourke, B., Effects of 4′-chlorodiazepam on cellular excitation-contraction coupling and ischaemia-reperfusion injury in rabbit heart. Cardiovasc. Res. 79 (2008), 141–149.
19. [19] Brown, D.A., Aon, M.A., Frasier, C.R., et al. Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization. J. Mol. Cell. Cardiol. 48 (2010), 673–679.
20. [20] Obame, F.N., Zini, R., Souktani, R., Berdeaux, A., Morin, D., Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J. Pharmacol. Exp. Ther. 323 (2007), 336–345.
21. [21] Xiao, J., Liang, D., Zhang, H., Liu, Y., Li, F., Chen, Y.H., 4′-Chlorodiazepam, a translocator protein (18 kDa) antagonist, improves cardiac functional recovery during postischemia reperfusion in rats. Exp. Biol. Med. (Maywood) 235 (2010), 478–486.
22. [22] Paradis, S., Leoni, V., Caccia, C., Berdeaux, A., Morin, D., Cardioprotection by the TSPO ligand 4′-chlorodiazepam is associated with inhibition of mitochondrial accumulation of cholesterol at reperfusion. Cardiovasc. Res. 98 (2013), 420–427.
23. [23] Cheng, K., Malliaras, K., Li, T.S., et al. Magnetic enhancement of cell retention, engraftment, and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion. Cell Transplant. 21 (2012), 1121–1135.
24. [24] Reffelmann, T., Kloner, R.A., Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am. J. Physiol. Heart Circ. Physiol. 283 (2002), H1099–H1107.
25. [25] Reffelmann, T., Kloner, R.A., The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res. Cardiol. 101:5 (2006 Sep), 359–372.
26. [26] Kloner, R.A., Hale, S.L., Dai, W., et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J. Am. Heart Assoc., 1, 2012, e001644.
27. [27] Pantsios, C., Kapelios, C., Vakrou, S., et al. Effect of elevated reperfusion pressure on “no reflow” area and infarct size in a porcine model of ischemia-reperfusion. J. Cardiovasc. Pharmacol. Ther. 21 (2016), 405–411.
28. [28] Fishbein, M.G., Meerbaum, S., Rit, J., et al. Early phase of acute myocardial infarct size quantification: validation of the triphenyltetrazolium chloride tissue enzyme staining technique. Am. Heart J. 101 (1981), 593–600.
29. [29] Malliaras, K., Li, T.S., Luthringer, D., Terrovitis, J., Cheng, K., Chakravarty, T., Galang, G., Zhang, Y., Schoenhoff, F., Van Eyk, J., Marbán, L., Marbán, E., Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125:1 (2012), 100–112.
30. [30] Reffelmann, T., Hale, S.L., Li, G., Kloner, R.A., Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 282:2 (2002), H766–H772.
31. [31] Veenman, L., Gavish, M., The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol. Ther. 110 (2006), 503–524.
32. [32] Leducq, N., Bono, F., Sulpice, T., et al. Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J. Pharmacol. Exp. Ther. 306 (2003), 828–837.
33. [33] Heusch, G., Libby, P., Gersh, B., et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383 (2014), 1933–1943.
34. [34] Burns, R.J., Gibbons, R.J., Yi, Q., et al. CORE study investigators. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J. Am. Coll. Cardiol. 39 (2002), 30–36.
35. [35] Larose, E., Rodes-Cabau, J., Pibarot, P., et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 55 (2010), 2459–2469.
36. [36] Skyschally, A., Schulz, R., Heusch, G., Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. Herz 33 (2008), 88–100.
37. [37] Niccoli, G., Lanza, G.A., Shaw, S., et al. Endothelin-1 and acute myocardial infarction: a no reflow mediator after successful percutaneous myocardial revascularization. Eur. Heart J. 27 (2006), 1793–1798.
38. [38] Takahashi, T., Hiasa, Y., Ohara, Y., et al. Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am. J. Cardiol. 100 (2007), 35–40.
39. [39] Campo, G., Valgimigli, M., Gemmati, D., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J. Am. Coll. Cardiol. 48 (2006), 2178–2185.